Posted by Michael Wonder on 05 Sep 2019
Tagrisso approved in China as a first-line treatment for EGFR-mutated non-small cell lung cancer
4 September 2019 - In the Phase III FLAURA trial, Tagrisso significantly increased the time patients lived without disease progression versus the comparator.
AstraZeneca today announced that it has received marketing authorisation from China’s National Medical Products Administration for Tagrisso (osimertinib) as a first-line treatment for adults with locally-advanced or metastatic non-small cell lung cancer whose tumours have the genetic mutations of epidermal growth factor receptor exon 19 deletions or exon 21 substitutions.
The approval followed the priority review pathway and is based on results from the Phase III FLAURA trial, which were published in The New England Journal of Medicine.
